科笛-B(02487.HK)公布两产品内地III期临床试验结果

阿斯达克财经
28 Nov 2024

科笛-B(02487.HK) 公布,其治疗雄激素性脱发产品CU-40102以及用于皮肤表皮手术的CU-30101的中国III期临床试验结果在全国美容皮肤科学大会(CDA年会)上公布。其中,CU-40102组的受试者的顶部秃发目标区域内的总毛发计数及终毛计数相比于基线改善均显著优于安慰剂组,达到主要终点指标和主要的次要终点指标,而且疗效从第12周起开始展现。至于CU-30101,其临床试验结果显示CU-30101与Pliaglis®镇痛疗效相当,达到主要终点。
两款产品的药品上市许可申请已在今年获国家药监局受理。(vc/u)

(港股报价延迟最少十五分钟。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10